Phase 1 Study of Cladribine Based Induction Therapy (CLAG) With ATRA (All-Trans Retinoic Acid) and Midostaurin in Relapsed/Refractory AML.

Trial Profile

Phase 1 Study of Cladribine Based Induction Therapy (CLAG) With ATRA (All-Trans Retinoic Acid) and Midostaurin in Relapsed/Refractory AML.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2014

At a glance

  • Drugs Midostaurin (Primary) ; Cladribine; Cytarabine; Granulocyte colony-stimulating factors; Tretinoin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms CLAG-ATRA-AML
  • Most Recent Events

    • 25 Oct 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 25 Oct 2010 Planned end date changed from 1 Sep 2012 to 1 Oct 2011 as reported by ClinicalTrials.gov.
    • 25 Oct 2010 Actual initiation date (Oct 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top